About this trial
This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
B. subtilis
Drug2 capsules, 3 times a day, orally taken for one month
Dead B. subtilis
Drug2 capsules, 3 times a day, orally taken for one month
Treatment groups
Trial outcomes
Primary outcomes
The score of IBS-SSS before and after intervention
Secondary outcomes
The concentration of purine in the stool before and after intervention
Sponsors and contacts
Click on the lead sponsor to view all of their trials.